|The somatic genomic landscape of glioblastoma|
CW Brennan, RGW Verhaak, A McKenna, B Campos, H Noushmehr, ...
Cell 155 (2), 462-477, 2013
|Integrated genomic characterization of endometrial carcinoma|
DA Levine, Cancer Genome Atlas Research Network
Nature 497 (7447), 67-73, 2013
|The molecular taxonomy of primary prostate cancer|
A Abeshouse, J Ahn, R Akbani, A Ally, S Amin, CD Andry, M Annala, ...
Cell 163 (4), 1011-1025, 2015
|The evolutionary history of lethal metastatic prostate cancer|
G Gundem, P Van Loo, B Kremeyer, LB Alexandrov, JMC Tubio, ...
Nature 520 (7547), 353-357, 2015
|Evaluation of methods for modeling transcription factor sequence specificity|
MT Weirauch, A Cote, R Norel, M Annala, Y Zhao, TR Riley, ...
Nature biotechnology 31 (2), 126, 2013
|Genomic alterations in cell-free DNA and enzalutamide resistance in castration-resistant prostate cancer|
AW Wyatt, AA Azad, SV Volik, M Annala, K Beja, B McConeghy, ...
JAMA oncology 2 (12), 1598-1606, 2016
|The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma|
BC Parker, MJ Annala, DE Cogdell, KJ Granberg, Y Sun, P Ji, X Li, ...
The Journal of clinical investigation 123 (2), 2013
|A prostate cancer susceptibility allele at 6q22 increases RFX6 expression by modulating HOXB13 chromatin binding|
Q Huang, T Whitington, P Gao, JF Lindberg, Y Yang, J Sun, MR Väisänen, ...
Nature genetics 46 (2), 126, 2014
|Circulating tumor DNA genomics correlate with resistance to abiraterone and enzalutamide in prostate cancer|
M Annala, G Vandekerkhove, D Khalaf, S Taavitsainen, K Beja, ...
Cancer discovery 8 (4), 444-457, 2018
|Concordance of circulating tumor DNA and matched metastatic tissue biopsy in prostate cancer|
AW Wyatt, M Annala, R Aggarwal, K Beja, F Feng, J Youngren, A Foye, ...
JNCI: Journal of the National Cancer Institute 109 (12), 2017
|Analysis of circulating cell-free DNA identifies multiclonal heterogeneity of BRCA2 reversion mutations associated with resistance to PARP inhibitors|
D Quigley, JJ Alumkal, AW Wyatt, V Kothari, A Foye, P Lloyd, R Aggarwal, ...
Cancer discovery 7 (9), 999-1005, 2017
|Insulin-like growth factor-binding protein 2-driven glioma progression is prevented by blocking a clinically significant integrin, integrin-linked kinase, and NF-κB network|
KM Holmes, M Annala, CYX Chua, SM Dunlap, Y Liu, N Hugen, ...
Proceedings of the National Academy of Sciences 109 (9), 3475-3480, 2012
|Treatment outcomes and tumor loss of heterozygosity in germline DNA repair–deficient prostate cancer|
M Annala, WJ Struss, EW Warner, K Beja, G Vandekerkhove, A Wong, ...
European urology 72 (1), 34-42, 2017
|Emergence of FGFR family gene fusions as therapeutic targets in a wide spectrum of solid tumours|
BC Parker, M Engels, M Annala, W Zhang
The Journal of pathology 232 (1), 4-15, 2014
|Circulating tumor DNA reveals clinically actionable somatic genome of metastatic bladder cancer|
G Vandekerkhove, T Todenhöfer, M Annala, WJ Struss, A Wong, K Beja, ...
Clinical cancer research 23 (21), 6487-6497, 2017
|A linear model for transcription factor binding affinity prediction in protein binding microarrays|
M Annala, K Laurila, H Lähdesmäki, M Nykter
PloS one 6 (5), 2011
|Fusion genes and their discovery using high throughput sequencing|
MJ Annala, BC Parker, W Zhang, M Nykter
Cancer letters 340 (2), 192-200, 2013
|Transcriptome sequencing reveals PCAT5 as a novel ERG-regulated long noncoding RNA in prostate cancer|
A Ylipää, K Kivinummi, A Kohvakka, M Annala, L Latonen, M Scaravilli, ...
Cancer research 75 (19), 4026-4031, 2015
|Integrative proteomics in prostate cancer uncovers robustness against genomic and transcriptomic aberrations during disease progression|
L Latonen, E Afyounian, A Jylhä, J Nättinen, U Aapola, M Annala, ...
Nature communications 9 (1), 1-13, 2018
|IGFBP2 potentiates nuclear EGFR–STAT3 signaling|
CY Chua, Y Liu, KJ Granberg, L Hu, H Haapasalo, MJ Annala, ...
Oncogene 35 (6), 738-747, 2016